<- Go home

Added to YB: 2018-07-23

Pitch date: 2018-07-23

TPIV [bearish]

Marker Therapeutics, Inc.

+98.44%

current return

Author Info

No bio for this author

Company Info

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

Market Cap

$11.9M

Pitch Price

$94.50

Price Target

N/A

Dividend

N/A

EV/EBITDA

N/A

P/E

-0.82

EV/Sales

-1.20

Sector

Biotechnology

Category

N/A

Show full summary:
TAPIMMUNE INC TPIV

A summary for this pitch has not been created yet.

Read full article (0 min)